Join us at ASCO 2024. Learn more
Region: United States
Events

2023 San Antonio
Breast Cancer Symposium®

December 5-9, 2023

Presentations of Interest

Click on abstract number to see the poster presented at SABCS 2023.


Oncotype DX Data

Update of RSClin® with extended TAILORx follow-up and development and validation of a new tool for risk of late distant recurrence
PO1-02-02 | Sparano

Concordance analysis of paired breast cancer core needle biopsies and surgical excision samples using the Oncotype DX Breast Recurrence Score® assay
PO4-08-09 | Nassar

Magnetic Resonance Imaging and a 12-Gene Expression Assay to Optimize Local Therapy for Ductal Carcinoma In Situ: 5-year clinical outcomes of E4112
GS03-01 | Khan

Impact of age and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Results from the multicenter ADAPTcycle trial (n=4,334).
LBO1-05  | Gluz


OncoExTra Data

Comparison of whole exome, whole transcriptome genomic profiling and targeted sequencing with 50-gene panels
PO5-13-05 | Thakkar

Classifying HER2-low breast cancer using a combination of ERBB2 mRNA expression and altered genes
PO5-13-06 | Basu

Prevalence of genomic alterations in Xerna tumor microenvironment subtypes in triple negative breast cancer patients
PO5-13-10 | Basu


PreventionGenetics Data

Cox: Hereditary cancer genetic testing in Puerto Rican females
PO1-08-08 | Cox

SYMPOSIUM PRESENTATION:

Insights for treatment decision making with the Oncotype DX Breast Recurrence Score® test and the RSClin® Tool


Learning Objectives

  • Recognize and discuss the increased prognostic information that may be offered to patients and clinicians by integrating the Oncotype DX Breast Recurrence Score® test with clinicopathologic characteristics
  • Describe the development and validation of the RSClin Tool for prognosis and prediction of chemotherapy benefit in patients with node-negative early-stage breast cancer
  • Analyze new updates to the RSClin Tool and interpret their effect on information offered by the tool
  • Introduce the RSClin Tool enhancement for late recurrence beyond 5 years and discuss its utility for patients and providers

 

Speakers
Jennifer Racz, MD

Director, Medical Affairs, Precision Oncology

Christy Russell, MD

Vice President, US Medical Affairs, Precision Oncology

Jay Andersen, MD

Co-Director, Compass Breast Specialists, Associate Chair, US Oncology Breast Cancer Research Committee

Dates
December 5-9, 2023
Contact Us

Have questions?

+1 866-662-6897

Email Customer Service

Contact Us